Want to see QTI full AI Analyst Report?
QTI Stock Chart & Stats
$5.95
--
Market closed
$5.95
--
Day’s Range― - ―
52-Week Range$2.64 - $9.21
Previous CloseN/A
VolumeN/A
Average Volume (3M)31.43K
Market Cap
$36.49M
Enterprise Value$97.62M
Total Cash (Recent Filing)$6.95M
Total Debt (Recent Filing)$5.80M
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding13,768,903
10 Day Avg. Volume22,708
30 Day Avg. Volume31,432
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)9.92
Price to Sales (P/S)3.38
P/FCF Ratio-7.04
Enterprise Value/Market Cap2.68
Enterprise Value/Revenue4.31
Enterprise Value/Gross Profit10.34
Enterprise Value/Ebitda-9.42
Forecast
1Y Price Target
$10.00Price Target Upside68.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$39.19M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Affirmed GuidanceRapid top-line expansion and an affirmed ~$39M 2026 target provide multi-quarter revenue visibility and validate initial commercial traction. Distributor-backed guidance and rising unit shipments increase the likelihood of sustained revenue scale and help absorb fixed costs as commercialization continues.
Material Multi-year Distributor CommitmentsLarge, multi-year minimum-order contracts create a committed backlog that improves demand visibility, supports production planning and de-risks near-term commercial adoption. Channel partnerships broaden geographic reach and lower direct sales costs relative to building a global direct footprint.
Regulatory Approvals And Clinical Validation ProgressOngoing regulatory clearances and clinical evidence (AMA Category III CPT code, FDA 510(k) enhancements, UAE clearance, Israeli registration) expand reimbursable use cases and international market access. These structural approvals materially increase long-term commercial addressability and payer/reimbursement pathways.
Bears Say
Cash Burn And Limited RunwayWith roughly $7M cash and quarterly operating cash use near $3.7M, the company faces a limited runway absent material margin improvement or fresh financing. Reliance on capital markets or debt increases dilution and refinancing risk over the next several quarters if FCF turnaround lags.
Meaningful Leverage And Higher Borrowing CostElevated leverage relative to equity and a repriced 12% senior loan raise fixed financing costs and reduce flexibility for a loss-making company. Higher interest expense and limited equity cushion heighten refinancing and liquidity risk during the scale-up phase.
Dependency On Distributors And Regulatory TimingA significant portion of near-term revenue is contingent on third-party distributor order fulfillment and timely regulatory clearances. Execution delays, SFDA questions, or regional shipping disruptions could materially defer revenue and weaken the projected path to break-even.
QT Imaging Holdings News
QTI FAQ
What was QT Imaging Holdings’s price range in the past 12 months?
QT Imaging Holdings lowest stock price was $2.64 and its highest was $9.21 in the past 12 months.
What is QT Imaging Holdings’s market cap?
QT Imaging Holdings’s market cap is $36.49M.
When is QT Imaging Holdings’s upcoming earnings report date?
QT Imaging Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 7 days.
How were QT Imaging Holdings’s earnings last quarter?
QT Imaging Holdings released its earnings results on May 13, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.135 by -$0.115.
Is QT Imaging Holdings overvalued?
According to Wall Street analysts QT Imaging Holdings’s price is currently Undervalued.
Does QT Imaging Holdings pay dividends?
QT Imaging Holdings does not currently pay dividends.
What is QT Imaging Holdings’s EPS estimate?
QT Imaging Holdings’s EPS estimate is -0.22.
How many shares outstanding does QT Imaging Holdings have?
QT Imaging Holdings has 13,768,903 shares outstanding.
What happened to QT Imaging Holdings’s price movement after its last earnings report?
QT Imaging Holdings reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.135. Following the earnings report the stock price went down -16.733%.
Which hedge fund is a major shareholder of QT Imaging Holdings?
Currently, no hedge funds are holding shares in QTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QT Imaging Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (68.07% Upside)
$10.00 (68.07% Upside)
Hedge Fund Trend
Decreased
By 66.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
274.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
102.75%
Trailing 12-Months
Company Description
QT Imaging Holdings
QT Imaging Holdings, Inc. is dedicated to the research, development, and manufacturing of advanced automated systems for breast imaging. These innovative devices are engineered to generate high-resolution ultrasound images utilizing transmission technology. The company's core product, the QT Ultrasound Breast Scanner, offers comprehensive reflection-mode and transmission-mode visualization of a patient's breast tissue. Established in 2011, QT Imaging Holdings, Inc. maintains its headquarters in Novato, California.
QTI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial, regulatory and clinical progress — including 133% year-over-year revenue growth, shipment increases, substantial multi-year distributor contracts, new CPT code approval, FDA enhancements clearance, UAE clearance, product/software advancements and improved GAAP loss and EBITDA trends. However, the company also faces margin compression (gross margin down from 65% to 41%), higher operating expenses and adjusted EBITDA weakness, modest cash on hand ($7.0M) versus ongoing quarterly cash burn (~$3.7M), and higher borrowing costs following a loan interest rate increase to 12%. Regulatory timing (e.g., SFDA) and geopolitical shipping disruptions also present execution risks. On balance, the positive commercial momentum, validated clinical data and significant distribution commitments outweigh near-term financial and operational headwinds, though execution on margin improvement, cash management and international approvals will be important to realize guidance.View all QTI earnings summariesQTI Stock 12 Month Forecast
Average Price Target
$10.00
▲(68.07% Upside)
Technical Analysis
Ownership Overview
14.43% Insiders
0.17% Mutual Funds
0.74% Other Institutional Investors
81.88% Public Companies and
Individual Investors